Company Filing History:
Years Active: 2012-2013
Title: Gary P. Schrum: Innovator in Heart Failure Treatment
Introduction
Gary P. Schrum is a notable inventor based in Maineville, OH (US). He has made significant contributions to the field of pharmacology, particularly in the development of inhibitors that target Protein Kinase C-alpha (PKC-α). With a total of 2 patents, his work is pivotal in advancing treatments for heart failure.
Latest Patents
Gary's latest patents include two innovative compounds. The first patent, titled "2-anilino-4-(heterocyclic)amino-pyrimidines," focuses on inhibitors that improve myocardial intracellular calcium cycling. This advancement is crucial for enhancing myocardial contraction and relaxation performance, ultimately slowing the progression of heart failure. The second patent, "2-anilino-4-aminoalkyleneaminopyrimidines," also targets PKC-α inhibitors, contributing similarly to the management of heart failure through improved cardiac function.
Career Highlights
Gary P. Schrum is associated with Boehringer Ingelheim International GmbH, where he continues to innovate in the pharmaceutical industry. His research and inventions are instrumental in developing new therapies that address critical health issues.
Collaborations
Gary has collaborated with notable coworkers, including Jane Far-Jine Djung and Adam A. Golebiowski. These partnerships enhance the research and development efforts within his field.
Conclusion
In summary, Gary P. Schrum is a distinguished inventor whose work in developing PKC-α inhibitors is vital for improving heart failure treatments. His contributions to pharmacology reflect a commitment to advancing medical science and patient care.